Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

John A. Thompson; Bryan J. Schneider; Julie Brahmer; Mohammad Abu Zaid; Amaka Achufusi; Philippe Armand; Meghan K. Berkenstock; Bonnie Bermas; Tawnie Braaten; Lihua E. Budde; Saurin Chokshi; Zachary D. Crees; Marianne Davies; Changchun Deng; Yaron Gesthalter; Michael Jain; Prantesh Jain; Andrew Jallouk; Benjamin H. Kaffenberger; Maya Khalil; Melissa G. Lechner; Tianhong Li; Alissa Marr; Suzanne McGettigan; Jordan McPherson; Theresa Medina; Nisha A. Mohindra; Anthony J. Olszanski; Olalekan Oluwole; Sandip P. Patel; Jason Prosek; Sunil Reddy; Pankti Reid; John Ryan; Mabel Ryder; Huda Salman; Bianca Santomasso; Scott Shofer; Jeffrey A. Sosman; Yinghong Wang; Vlad G. Zaha; Stephen Zucker; Megan Lyons; Ajibola Awotiwon; Lisa Hang

doi:10.6004/jnccn.2024.0057

Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi, Philippe Armand, Meghan K. Berkenstock, Bonnie Bermas, Tawnie Braaten, Lihua E. Budde, Saurin Chokshi, Zachary D. Crees, Marianne Davies, Changchun Deng, Yaron Gesthalter, Michael Jain, Prantesh Jain, Andrew Jallouk, Benjamin H. Kaffenberger, Maya KhalilMelissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan McPherson, Theresa Medina, Nisha A. Mohindra, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Jason Prosek, Sunil Reddy, Pankti Reid, John Ryan, Mabel Ryder, Huda Salman, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Stephen Zucker, Megan Lyons, Ajibola Awotiwon, Lisa Hang

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

Original language	English
Pages (from-to)	582-592
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	22
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2024.0057
State	Published - Nov 2024

Access to Document

10.6004/jnccn.2024.0057

Cite this

Thompson, J. A., Schneider, B. J., Brahmer, J., Zaid, M. A., Achufusi, A., Armand, P., Berkenstock, M. K., Bermas, B., Braaten, T., Budde, L. E., Chokshi, S., Crees, Z. D., Davies, M., Deng, C., Gesthalter, Y., Jain, M., Jain, P., Jallouk, A., Kaffenberger, B. H., ... Hang, L. (2024). Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 22(9), 582-592. https://doi.org/10.6004/jnccn.2024.0057

@article{c2e4033ceabf4f7db7a7ae9422213d97,

title = "Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.",

author = "Thompson, \{John A.\} and Schneider, \{Bryan J.\} and Julie Brahmer and Zaid, \{Mohammad Abu\} and Amaka Achufusi and Philippe Armand and Berkenstock, \{Meghan K.\} and Bonnie Bermas and Tawnie Braaten and Budde, \{Lihua E.\} and Saurin Chokshi and Crees, \{Zachary D.\} and Marianne Davies and Changchun Deng and Yaron Gesthalter and Michael Jain and Prantesh Jain and Andrew Jallouk and Kaffenberger, \{Benjamin H.\} and Maya Khalil and Lechner, \{Melissa G.\} and Tianhong Li and Alissa Marr and Suzanne McGettigan and Jordan McPherson and Theresa Medina and Mohindra, \{Nisha A.\} and Olszanski, \{Anthony J.\} and Olalekan Oluwole and Patel, \{Sandip P.\} and Jason Prosek and Sunil Reddy and Pankti Reid and John Ryan and Mabel Ryder and Huda Salman and Bianca Santomasso and Scott Shofer and Sosman, \{Jeffrey A.\} and Yinghong Wang and Zaha, \{Vlad G.\} and Stephen Zucker and Megan Lyons and Ajibola Awotiwon and Lisa Hang",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2024",

month = nov,

doi = "10.6004/jnccn.2024.0057",

language = "English",

volume = "22",

pages = "582--592",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "9",

}

Thompson, JA, Schneider, BJ, Brahmer, J, Zaid, MA, Achufusi, A, Armand, P, Berkenstock, MK, Bermas, B, Braaten, T, Budde, LE, Chokshi, S, Crees, ZD, Davies, M, Deng, C, Gesthalter, Y, Jain, M, Jain, P, Jallouk, A, Kaffenberger, BH, Khalil, M, Lechner, MG, Li, T, Marr, A, McGettigan, S, McPherson, J, Medina, T, Mohindra, NA, Olszanski, AJ, Oluwole, O, Patel, SP, Prosek, J, Reddy, S, Reid, P, Ryan, J, Ryder, M, Salman, H, Santomasso, B, Shofer, S, Sosman, JA, Wang, Y, Zaha, VG, Zucker, S, Lyons, M, Awotiwon, A & Hang, L 2024, 'Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 22, no. 9, pp. 582-592. https://doi.org/10.6004/jnccn.2024.0057

TY - JOUR

T1 - Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

AU - Thompson, John A.

AU - Schneider, Bryan J.

AU - Brahmer, Julie

AU - Zaid, Mohammad Abu

AU - Achufusi, Amaka

AU - Armand, Philippe

AU - Berkenstock, Meghan K.

AU - Bermas, Bonnie

AU - Braaten, Tawnie

AU - Budde, Lihua E.

AU - Chokshi, Saurin

AU - Crees, Zachary D.

AU - Davies, Marianne

AU - Deng, Changchun

AU - Gesthalter, Yaron

AU - Jain, Michael

AU - Jain, Prantesh

AU - Jallouk, Andrew

AU - Kaffenberger, Benjamin H.

AU - Khalil, Maya

AU - Lechner, Melissa G.

AU - Li, Tianhong

AU - Marr, Alissa

AU - McGettigan, Suzanne

AU - McPherson, Jordan

AU - Medina, Theresa

AU - Mohindra, Nisha A.

AU - Olszanski, Anthony J.

AU - Oluwole, Olalekan

AU - Patel, Sandip P.

AU - Prosek, Jason

AU - Reddy, Sunil

AU - Reid, Pankti

AU - Ryan, John

AU - Ryder, Mabel

AU - Salman, Huda

AU - Santomasso, Bianca

AU - Shofer, Scott

AU - Sosman, Jeffrey A.

AU - Wang, Yinghong

AU - Zaha, Vlad G.

AU - Zucker, Stephen

AU - Lyons, Megan

AU - Awotiwon, Ajibola

AU - Hang, Lisa

PY - 2024/11

Y1 - 2024/11

N2 - The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

AB - The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85209385988&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.0057

DO - 10.6004/jnccn.2024.0057

M3 - Article

C2 - 39536465

AN - SCOPUS:85209385988

SN - 1540-1405

VL - 22

SP - 582

EP - 592

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this